TrialJournal of neurology, neurosurgery, and psychiatry2023

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.

Xavier Montalban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.